Breast surgery was excluded, and a therapy with aromatase inhibitors was started; in the meantime, due to the commercial unavailability of Vandetanib, in December 2022, treatment with cabozantinib was started at a reduced dose of 60 mg daily, considering both the patient’s age and the liver failure. Here, CYP19A1 is linked to Hepatic failure.